{"a":[{"_":"AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report","$":{"href":"/cro/ai-clinical-monitoring-agents-can-deliver-82-times-roi-report","hreflang":"en"}}]}

Summary

A Tufts Center for the Study of Drug Development analysis reports that AI clinical monitoring agents can deliver up to 82-fold return on investment in phase 3 oncology trials. This is a research finding on AI efficiency in clinical trial monitoring with no specific drug or company development involved.